Dabrafenib in combination with trametinib clinical trials

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

The DETERMINE trial is testing if existing cancer medicines can help people with rare cancers or common cancers with rare genetic changes. It includes adults, teenagers, and children. The goal is to find new ways to treat cancer and make these treatments available through the NHS.